Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Saved in:
| Title: | Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. |
|---|---|
| Authors: | Blackwell, K. L.1 black034@mc.duke.edu, Pegram, M. D.2, Tan-Chiu, E.3, Schwartzberg, L. S.4, Arbushites, M. C.5, Maltzman, J. D.5, Forster, J. K.5, Rubin, S. D.5, Stein, S. H.5, Burstein, H. J.6 |
| Source: | Annals of Oncology. Jun2009, Vol. 20 Issue 6, p1026-1031. 6p. 4 Charts, 2 Graphs. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
